ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults


ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®

  • The United States Food and Drug Administration (FDA) has issued a Complete Response Letter. In this letter, the FDA informs ROVI that it considers the responses to the evaluation of the Risvan® dossier to be complete and makes no additional observations.
  • The letter states that ROVI must close the observations made by the FDA during its inspection in May 2023. ROVI will submit a response to reinitiate the procedure providing details of the responses that have already been filed. ROVI will then await a further notification from the FDA with the estimated User Fee Goal Date for the closure of the procedure, which is expected to be in February 2024.
  • There are no observations that have not yet been resolved by ROVI’s suppliers.
Average: 3.7 (3 votes)
 
Related
Madrid, Spain - 24 October 2024 – Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical company that...
2 min
24/10/2024
ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS Operating revenue in...
7 min
31/07/2024
The Community of Madrid has declared this project to be strategic: it will create 200 new direct jobs for 2027 and raise the plant’s...
4 min
11/07/2024